The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
Sponsor: Eli Lilly and Company
Listed as NCT06383390, this PHASE3 trial focuses on Atherosclerotic Cardiovascular Disease (ASCVD) and Chronic Kidney Disease (CKD) and remains ongoing. Sponsored by Eli Lilly and Company, it has been updated 20 times since 2024, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
20 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
▶ Show 15 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE3
-
Oct 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2024 — Jun 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Apr 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aabenraa, Denmark , Aalst, Belgium , Aarhus, Denmark , Aberdeen, United Kingdom , Actopan, Mexico , Acworth, United States , Adelaide, Australia , Afyonkarahisar, Turkey (Türkiye) , Aguascalientes, Mexico and 523 more locations